Last reviewed 2026-04-23 · How we verify

modified FOLFOX6 + bevacizumab

modified FOLFOX6 + bevacizumab is a Chemotherapy combination + monoclonal antibody Small molecule drug developed by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). It is currently in Phase 3 development for Metastatic colorectal cancer.

Modified FOLFOX6 chemotherapy combined with bevacizumab inhibits tumor cell division and blocks new blood vessel formation to starve tumors of nutrients.

Modified FOLFOX6 chemotherapy combined with bevacizumab inhibits tumor cell division and blocks new blood vessel formation to starve tumors of nutrients. Used for Metastatic colorectal cancer.

At a glance

Mechanism of action

Modified FOLFOX6 is a chemotherapy regimen containing fluorouracil, leucovorin, and oxaliplatin that damages DNA and prevents cancer cell replication. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) that inhibits angiogenesis, reducing blood supply to tumors. Together, they provide dual mechanisms of cytotoxic chemotherapy and anti-angiogenic therapy.

Approved indications

• Metastatic colorectal cancer

Common side effects

• Neutropenia
• Peripheral neuropathy
• Diarrhea
• Nausea/vomiting
• Hypertension
• Proteinuria
• Bleeding

Key clinical trials

• A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
• Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
• A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (PHASE3)
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (PHASE3)
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (PHASE1, PHASE2)
• EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
• Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• modified FOLFOX6 + bevacizumab CI brief — competitive landscape report
• modified FOLFOX6 + bevacizumab updates RSS · CI watch RSS
• Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) portfolio CI

Frequently asked questions about modified FOLFOX6 + bevacizumab

Related

• Drug class: All Chemotherapy combination + monoclonal antibody drugs
• Target: All drugs targeting DNA (chemotherapy); VEGF (bevacizumab)
• Manufacturer: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Metastatic colorectal cancer
• Compare: modified FOLFOX6 + bevacizumab vs similar drugs
• Pricing: modified FOLFOX6 + bevacizumab cost, discount & access